Intech Investment Management LLC Acquires New Holdings in Artivion, Inc. (NYSE:AORT)

Intech Investment Management LLC acquired a new stake in Artivion, Inc. (NYSE:AORT) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,877 shares of the company’s stock, valued at approximately $253,000.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after purchasing an additional 505 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Artivion by 3.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock worth $510,000 after purchasing an additional 600 shares during the last quarter. Texas Permanent School Fund Corp boosted its stake in shares of Artivion by 2.0% during the 1st quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock worth $722,000 after purchasing an additional 677 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Artivion during the 2nd quarter worth about $28,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Artivion by 5.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock worth $713,000 after purchasing an additional 1,634 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on AORT. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Artivion in a report on Friday. Lake Street Capital increased their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Oppenheimer increased their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Stifel Nicolaus increased their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 3,167 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.55, for a total value of $84,083.85. Following the transaction, the senior vice president now owns 161,932 shares in the company, valued at $4,299,294.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the sale, the senior vice president now owns 161,932 shares in the company, valued at $4,299,294.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Anthony B. Semedo sold 9,709 shares of Artivion stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the sale, the director now owns 34,159 shares in the company, valued at approximately $853,633.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,679 shares of company stock worth $626,518. Company insiders own 8.10% of the company’s stock.

Artivion Trading Up 4.2 %

NYSE AORT opened at $26.85 on Friday. Artivion, Inc. has a one year low of $12.16 and a one year high of $29.24. The company’s 50 day moving average price is $25.84 and its 200 day moving average price is $23.86. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -111.88 and a beta of 1.74.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The firm had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. On average, sell-side analysts predict that Artivion, Inc. will post 0.2 EPS for the current year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.